Committee Composition

Below is a summary of our committee structure and membership information. To read more about any of the committees, click on committee names in the chart below.
Chairperson Chairperson     Committee Member Member     Financial Expert Financial Expert    
 Board of Directors Nomination and Corporate Governance CommitteeCompensation Committee Audit Committee
Ton Logtenberg, Ph.D 
Ton Logtenberg, Ph.D
CEO, Executive Director


Ton Logtenberg has served as our Chief Executive Officer and as board member since co-founding our Company in June 2003. Prior to joining Merus, Dr. Logtenberg co-founded Crucell N.V., a biotechnology company specializing in vaccines and biopharmaceutical technology, and served as its executive vice president and chief scientific officer from July 2000 until November 2003. Dr. Logtenberg has served as a member of the board of directors of the Jenner Foundation since 2008 and a member of the b... 

Committee Member    
Russell Greig 
Russell Greig
Chairman, Non-Executive Director


Dr Russell Greig is Chairman of our board of directors and has been a member of the board since July 2018. With more than 35 years’ experience in the pharmaceutical and biotechnology industry, Dr Greig has extensive expertise in research and development, business development and commercial operations. Dr Greig worked at GlaxoSmithKline for three decades, most recently as President of SR One, GlaxoSmithKline’s corporate venture group. Prior to joining SR One, he served as President of GlaxoSmi... 

Chairperson Chairperson   
Mark  Iwicki 
Mark  Iwicki
Non- Executive Director


Mark Iwicki has been a member of the board since June 2015. Mr. Iwicki also serves as the chief executive officer and chairman of the board of directors of Kala Pharmaceuticals, Inc. and as a member of the boards of directors of Aimmune Therapeutics, Inc., Nimbus Therapeutics, TARIS Biomedical and Oxeia Biopharmaceuticals. In addition, Mr. Iwicki has served on the board of the Wellesley Youth Hockey Association. Mr. Iwicki served as president and chief executive officer and a member of the bo... 

Committee Member Committee Member Chairperson  
John de Koning, Ph.D. 
John de Koning, Ph.D.
Non-Executive Director


John de Koning, Ph.D. has been a member of the board since January 2010. Dr. de Koning has been a partner at Life Sciences Partners since January 2006. Dr. de Koning has served as a member of the board of directors of arGEN-X since September 2009 and currently serves on the boards of several private companies. Previously, he served on the supervisory boards of BMEYE (acquired by Edwards Lifesciences), Prosensa (acquired by BioMarin) and Skyline Diagnostics, and as a non-executive director on ... 

Committee Member Committee Member   Committee Member
Gregory  Perry Financial Expert
Gregory  Perry
Non-Executive Director


Gregory Perry has been a member of our board since May 2016. Mr. Perry has been the chief financial and administrative officer of Novelion Therapeutics, a biopharmaceutical company, since July 2015. Prior to joining Novelion Therapeutics, Mr. Perry served as chief financial and business officer of Eleven Biotherapeutics, Inc., a biopharmaceutical company, from December 2013 to July 2015, as interim chief financial officer of InVivo Therapeutics Holding Corp., a biotechnology company, from Sep... 

Committee Member   Committee Member Chairperson
Anand  Mehra, M.D. 
Anand  Mehra, M.D.
Non-Executive Director


Anand Mehra, M.D. has been a member of the board since August 2015. Dr. Mehra has been with Sofinnova Ventures since 2007, most recently holding the position of a general partner where he focuses on working with entrepreneurs to build drug development companies. He has led the firm’s investments in Vicept Therapeutics (acquired by Allergan), Aerie Pharmaceuticals, Inc., Aclaris Therapeutics, Inc., and Prothena Corporation PLC. He currently serves as a member of the boards of directors of Spar... 

Committee Member    Committee Member
Len Kanavy 
Len Kanavy
Non-Executive Director


Mr Len Kanavy has been a member of the board since July 2018. Mr Kanavy most recently served as Senior Vice President, Commercial Business Operations at Genentech where he was responsible for strategic decisions of the US commercial business including product launches, valuation of business development opportunities, clinical development plan options and pricing. He was a member of the Commercial Leadership Committee and a Board Member of the Genentech Access to Care Foundation. Prior to joining... 
Committee Member   Committee Member  

RSS FeedsFinancial Tear SheetE-mail PagePrint PageE-mail Alerts